Cytori Therapeutics Inc. (NASDAQ:CYTX)’s share price rose 3.1% during mid-day trading on Friday . The stock traded as high as $2.04 and last traded at $2.02, with a volume of 69,700 shares changing hands. The stock had previously closed at $1.96.

CYTX has been the topic of several recent analyst reports. Maxim Group reaffirmed a “buy” rating and set a $75.00 price objective on shares of Cytori Therapeutics in a report on Thursday, March 31st. Roth Capital initiated coverage on shares of Cytori Therapeutics in a research note on Monday, March 28th. They issued a “buy” rating and a $22.50 price target on the stock. Finally, Zacks Investment Research raised shares of Cytori Therapeutics from a “hold” rating to a “buy” rating and set a $2.25 price target on the stock in a research note on Tuesday, July 12th.

The firm has a 50-day moving average of $2.19 and a 200-day moving average of $2.87. The firm’s market cap is $27.00 million.

Cytori Therapeutics (NASDAQ:CYTX) last announced its earnings results on Tuesday, May 10th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.03) by $0.38. The firm had revenue of $2.90 million for the quarter, compared to analyst estimates of $2.05 million. Cytori Therapeutics’s revenue for the quarter was up 26.1% on a year-over-year basis. During the same quarter last year, the firm earned ($0.07) earnings per share. On average, analysts anticipate that Cytori Therapeutics Inc. will post ($1.59) EPS for the current year.

Cytori Therapeutics, Inc (Cytori) is a biotechnology company involved in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company is engaged in developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns combined with radiation injury.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.